News FocusAIDS Research

# Vaccine Studies Stymied by Shortage of Animals

See allHide authors and affiliations

Science  11 Feb 2000:
Vol. 287, Issue 5455, pp. 959-960
DOI: 10.1126/science.287.5455.959

NIH doesn't know how many Indian rhesus macaques its researchers need, nor how many are available. And that's a big problem

Paul Johnson's lab at the New England Regional Primate Research Center is one of the best equipped in the world to study the immunology of SIV, the simian AIDS virus. Johnson also enjoys generous funding from the National Institutes of Health (NIH). So why does he have to wait 2 to 6 months to start an experiment? The answer is simple: The demand for rhesus macaques, the animal of choice for Johnson and a growing number of AIDS researchers, far outstrips the supply. But the reasons for that shortage are complex, encompassing everything from international trade to internal NIH politics. And AIDS researchers are worried that, if the shortage persists, it could hinder progress in the field. “It's a huge problem,” says Norman Letvin, a leading AIDS vaccine researcher based at Harvard's Beth Israel Deaconess Medical Center in Boston. “And it's going to get much worse.”

For many years, AIDS researchers bemoaned the lack of a good animal model for testing vaccines, measuring the toxicity of various drugs, and exploring the disease's progression. But the Indian rhesus macaque was found to develop a disease that closely mimics human AIDS when infected by SIV and has steadily gained in popularity. NIH has stimulated the demand for these monkeys by doubling its budget in the past 5 years for AIDS vaccine research. To make matters worse, researchers in reproductive biology, malaria, and other fields also have begun to rely more heavily on rhesus macaques.

But supplies are limited. India, once the main source, has banned exports of the species since 1978, and NIH is phasing out a domestic program to breed “clean” macaques that was begun after many imported monkeys were found to harbor pathogens. The resulting imbalance between supply and demand has caused delays of up to a year or more for animals with certain genetic features and has driven up the price of the animals to a level that is straining many researchers' budgets.

Six months ago NIH's Office of AIDS Research (OAR) sponsored a meeting at which researchers concluded that there was a “severe shortage” of rhesus macaques and urged NIH to act quickly. But NIH officials say it's not clear what should be done, or which component of the $18 billion agency should take the lead. “There is a problem, but I'm not able at present to identify its dimensions,” says OAR director Neal Nathanson. The issue, he says, falls in the lap of another NIH branch, the National Center for Research Resources (NCRR), which in addition to funding the New England facility and seven other primate facilities specifically bankrolls breeding programs with both nonprofit and commercial suppliers. “I've conveyed my sense of the [problem] to NCRR,” Nathanson says. Some outside researchers wonder, however, if NCRR has the ability or desire to improve the situation. “It's a very isolated institute, and it doesn't collaborate well with other institutes,” says Alan Schultz, a former head of AIDS vaccine research at the National Institute of Allergy and Infectious Diseases who now works with the International AIDS Vaccine Initiative. Jerry Robinson, who oversees the regional primate centers for NCRR, agrees that there is a “real crisis.” But Robinson has had difficulty assessing the number of primates available for research, and no one at NCRR has tallied the number of animals required by NIH-funded researchers. Several factors complicate any attempt to make even a simple assessment of the available population, says Robinson. Primate centers and private colonies reserve some animals for breeding or behavioral research, and disqualify others that are too young or old. In addition, both commercial breeders and primate centers have been known to play favorites. “The people involved in monkey procurement seem like an old boys' network of people calling their friends,” says New England's Johnson. “Two people may call up and get different information about availability.” In addition, one size definitely doesn't fit all researchers. Scientists have become increasingly selective as they develop more sophisticated research tools and reagents. But the cost of many of the animals produced through NCRR-funded breeding programs now far exceeds that budgeted in the average NIH-funded grant. Add in the rising demand from outside the AIDS field and the result, Robinson says, is that “lots of NIH grants depend on macaques, and [the researchers] can't get the monkeys they need.” Most in demand are monkeys that don't have chronic infections. In the early 1980s, coincident with the start of the AIDS epidemic, primate researchers discovered that many rhesus macaques had been infected with what is now known as simian retrovirus. Although the virus has no relationship to SIV or HIV, it can kill monkeys from an AIDS-like disease. Many animals also harbored an array of other viruses that could either harm the monkeys or their handlers, including STLV, herpes B, and foamy. So 12 years ago, NCRR decided to fund select primate centers and commercial outfits to breed “specific pathogen free” (SPF) animals. Unfortunately, the SPF breeding program has done little to alleviate the crunch, and rising demand has driven up prices. Kay Izard, a zoologist who runs the SPF program at LABS of Virginia in Yemassee, South Carolina, says the top asking price for an SPF animal has risen from$2000 in 1987 to \$5000 today. That's nearly double the per capita price budgeted by most NIH-funded researchers, some of whom buy as many as 100 rhesus macaques a year.

Three years ago, NCRR decided to phase out funding for the SPF breeding program. It was a tacit admission that the animals had become too expensive for academic researchers and that the program was instead subsidizing commercial users. “The long-range goal of NCRR was to set these colonies up and not to subsidize them forever,” says Robinson. But Izard and others have questioned that decision. “It's too bad they didn't extend the funding for it, since there is a real problem,” says Izard, noting that they have had to raise prices even higher since NCRR cut its support.

On top of the shortage of SPF animals, AIDS researchers are also hard pressed to find females of breeding age, as well as a specific genetic type used for immunologic studies that help explain why vaccines fail or succeed. Specifically, researchers have developed reagents that allow them to measure killer cells—a critical component of the immune system—only in animals that have a marker on their white blood cells known as Mamu-A*01. “The wait for Mamu-A*01 animals is not quantified in months but in years,” says Johnson.

NCRR soon will solicit new proposals from monkey breeders, says Robinson, in hopes of boosting supply. But new housing for breeding colonies is also essential, says Ronald Desrosiers, who heads the New England center in Southborough, Massachusetts. “You can give me all the [breeding] money you want,” he says, “but if I can't use it to build a building to put them in and the infrastructure to support it, it is impossible [to produce more animals].” Others suggest that centers in cold climates like New England should instead contract out the work to commercial firms in warmer climates, where animals can roam outside all year.

Some researchers see foreign stocks as a partial solution. Marta Marthas of the California Regional Primate Research Center in Davis says researchers should look more carefully at rhesus macaques still available from China. Although studies suggest that Chinese macaques naturally control SIV infection more effectively than do monkeys of Indian origin, Marthas says many questions remain about their differences. David Watkins of the University of Wisconsin, Madison, hopes to implant embryos from Indian Mamu-A*01 animals into Chinese rhesus mothers. “[In vitro fertilization] is the way to go,” he says, although he adds that the technique is now inefficient.

Whatever its cause, the shortage of rhesus macaques has highlighted the need for scientists to become more involved in breeding them. “What disturbs me the most is that this [issue] is looked at with great disdain by everyone,” says Marthas. “We have to think ahead. If we don't, we'll jeopardize not only our own experiments but those of future scientists.”